Screening for liver fibrosis in the general population: a call for action

The Lancet Gastroenterology and Hepatology

Volumn 1, Issue 3, 2016, Pages 256-260

  Ginès, Pere ^a,b   Graupera, Isabel ^a,b   Lammert, Frank ^c   Angeli, Paolo ^d   Caballeria, Llorenç ^b,e   Krag, Aleksander ^f   Guha, I Neil ^g   Murad, S Darwish ^h   Castera, Laurent ^i,j  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c SAARLAND UNIVERSITY   (Germany)

^d UNIVERSITY OF PADOVA   (Italy)

^e Research Institute University Primary Care IDIAP Jordi Gol   (Spain)

^f ODENSE UNIVERSITY HOSPITAL   (Denmark)

^g UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ BEAUJON HOSPITAL   (France)

^j UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN;

CHRONIC LIVER DISEASE; DEATH; DISEASE ASSOCIATION; EARLY DIAGNOSIS; FIBROSIS; HUMAN; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER STIFFNESS; META ANALYSIS (TOPIC); NONALCOHOLIC FATTY LIVER; NOTE; POPULATION; PRIORITY JOURNAL; TRANSIENT ELASTOGRAPHY; BLOOD; CHRONIC DISEASE; ELASTOGRAPHY; MASS SCREENING; PROCEDURES;

BIOMARKERS; CHRONIC DISEASE; EARLY DIAGNOSIS; ELASTICITY IMAGING TECHNIQUES; HUMANS; LIVER CIRRHOSIS; MASS SCREENING;

EID: 84996539935     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(16)30081-4     Document Type: Note

References (37)

1. 1 GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385 (2015), 117–171.
2. 2 Volk, ML, Tocco, RS, Bazick, J, Rakoski, MO, Lok, AS, Hospital readmissions among patients with decompensated cirrhosis. Am J Gastroenterol 107 (2012), 247–252.
3. 3 Morando, F, Maresio, G, Piano, S, et al. How to improve care in outpatients with cirrhosis and ascites: a new model of care coordination by consultant hepatologists. J Hepatol 59 (2013), 257–264.
4. 4 Schuppan, D, Afdhal, NH, Liver cirrhosis. Lancet 371 (2008), 838–851.
5. 5 Ray, K, NAFLD—the next global epidemic. Nat Rev Gastroenterol Hepatol, 10, 2013, 621.
6. 6 Lee, YA, Wallace, MC, Friedman, SL, Pathobiology of liver fibrosis: a translational success story. Gut 64 (2015), 830–841.
7. 7 Williams, R, Aspinall, R, Bellis, M, et al. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet 384 (2014), 1953–1997.
8. 8 Poynard, T, Bedosa, P, Opolon, P, Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINVIR, and DOSVIRC groups. Lancet 349 (1997), 825–832.
9. 9 Angulo, P, Kleiner, DE, Dam-Larsen, S, et al. Liver fibrosis, but no other histological features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149 (2015), 389–397.
10. 10 European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 63 (2015), 237–264.
11. 11 Friedrich-Rust, M, Poynard, T, Castera, L, Critical comparison of elastography methods to assess chronic liver disease. Nat Rev Gastroenterol Hepatol 13 (2016), 402–411.
12. 12 Thiele, M, Detlefsen, S, Sevelsted Møller, L, et al. Transient and 2-dimensional shear-wave elastography provide comparable assessment of alcoholic liver fibrosis and cirrhosis. Gastroenterology 150 (2016), 123–133.
13. 13 Ratziu, V, Massard, J, Charlotte, F, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol, 6, 2006, 6.
14. 14 Guha, IN, Parkes, J, Roderick, P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple markers. Hepatology 47 (2008), 455–460.
15. 15 Calès, P, Lainé, F, Boursier, J, et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 50 (2009), 165–173.
16. 16 Shah, AG, Lydecker, A, Murray, K, Tetri, BN, Contos, MJ, Sanyal, AJ, Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 7 (2009), 1104–1112.
17. 17 McPherson, S, Stewart, SF, Henderson, E, Burt, AD, Day, CP, Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 59 (2010), 1265–1269.
18. 18 Angulo, P, Hui, JM, Marchesini, G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45 (2007), 846–854.
19. 19 Ratziu, V, Giral, P, Munteanu, M, et al. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia. Aliment Pharmacol Ther 25 (2007), 207–218.
20. 20 Jacqueminet, S, Lebray, P, Morra, R, et al. Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes. Clin Gastroenterol Hepatol 6 (2008), 828–831.
21. 21 Poynard, T, Lebray, P, Ingiliz, P, et al. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (Fibro Test). BMC Gastroenterol, 10, 2010, 40.
22. 22 Roulot, D, Costes, JL, Buyck, JF, et al. Transient elastography as screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut 60 (2011), 977–984.
23. 23 Koehler, EM, Plompen, EP, Schouten, JN, et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study. Hepatology 63 (2016), 138–147.
24. 24 Kwok, R, Choi, KC, Wong, GL, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut 65 (2016), 1359–1368.
25. 25 Harman, DJ, Ryder, SD, James, MW, et al. Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography. BMJ Open, 5, 2015, e007516.
26. 26 European Association for the Study of the Liver European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64 (2016), 1388–1402.
27. 27 European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 63 (2015), 199–236.
28. 28 European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 57 (2012), 167–185.
29. 29 European Association for the Study of the Liver. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 53 (2010), 3–22.
30. 30 European Association for the Study of the Liver. EASL clinical practice guidelines: management of alcoholic liver disease. J Hepatol 57 (2012), 399–420.
31. 31 European Association for the Study of the Liver. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol 63 (2015), 971–1004.
32. 32 European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 51 (2009), 237–267.
33. 33 European Association for the Study of the Liver. EASL clinical practice guidelines: Wilson's disease. J Hepatol 56 (2012), 671–685.
34. 34 Vilar-Gomez, E, Martinez-Perez, Y, Calzadilla-Bertot, L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149 (2015), 367–378.
35. 35 Lassailly, G, Caiazzo, R, Buob, D, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology 149 (2015), 379–388.
36. 36 Neuschwander-Tetri, BA, Loomba, R, Sanyal, AJ, et al., NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385 (2015), 956–965.
37. 37 Ratziu, V, Harrison, SA, Francque, S, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 150 (2016), 1147–1159.